The Clinical Observation About The Efficacy And Safety Of The Autologous Bone Marrow Mononuclear Cells In The Treatment Of The Heart Failure In Non Ischemic Cardiomyopathy

Background:Heart failure is the performance of end stage of various heart diseases. Recently, With the development of revascularization and a large number of new and special drugs, we have made the remarkable development in the treatment of the heart failure of ischemic cardiom-yopathy But for the heart failure of non ischemic cardiomyopathy,there are only the three methods:.the diuretic, the vasodilator, and strong heart. It is the main cause of death that heart failure in the patients of Non ische-mic cardiomyopathy. After a large number of studies Ester Macia[1] and Martin-Rendon[2]haved confirmed that stem cells and bone marrow cells was a kind of new method in treating the heart failure. Bone marrow mononuclear cells is a general term for mononuclear cells in bone marrow cells, includes the original variety cells and cytokines cells, progenitor cells and different stages of differentiation from. In the first Strauer and Silva[3] treated heart failure after myocardial infarction and to evaluate its efficacy and safety with the ABMMNC.Objective:To observe the safety and efficacy of autologous bone marrow mononuclear cells percutaneous coronary transplantation in the treatment of non ischemic cardiomyopathyMethods:There are 40 cases in the Affiliated Hospital of Inner Mongolia Medical University.,and 25 cases of experimental group,15 cases of the control group.Follow-up 24 months, about UCG、PET-CT、 BNP、6Minutes Walking Tes、Minnesota quality of Life Scale ect.Resolute:25 case in experimental group have been given autologous bone marrow mononuclear cells through percutaneous coronary.All completed the follow-up.6Minutes Walking Test preoperative 130±60 m increased to190±50 m, The defect size of Myocardial metabolic reduced from 43.79±17.99cm3 to 28.19 ±9.27cm3 left ventricular end-diastolic from 64±8mm to 59±7mm left ventricular ejection fraction, preo-perative (27±6)%improvement to postoperative (45±4)%, p<0.05.No serious complications associated with BMMNCs injection, including ventricular arrhythmia and death.Conclusion:The method treating heart failure in the patients of with non ischemic cardiomyopathy.with autologous in bone marrow mononuclear cells...